Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patient Exclusion Analysis Coming From FDA; Changes In Trial Recruitment Could Follow

This article was originally published in The Pink Sheet Daily

Executive Summary

Subjects with psychiatric conditions are often excluded from trials, an agency study finds, which “doesn’t seem a good thing” to Bob Temple.

You may also be interested in...



FDA’s Clinical Trial Inclusion Policy Sold As Mild And Gentle

Bob Temple says encouraging broader populations in clinical trials should not affect study size or enrichment designs.

FDA’s Clinical Trial Inclusion Policy Sold As Mild And Gentle

Bob Temple says encouraging broader populations in clinical trials should not affect study size or enrichment designs.

FDA To Be More Vigilant About Proposed Clinical Trial Exclusions

FDA’s Bob Temple says “document” being drafted will instruct reviewers to pay more attention during sponsor meetings and eliminate unnecessary exclusions from protocols.

Related Content

Topics

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel